TorreyPines is looking to sell its other discovery assets to focus on development.
TorreyPines Therapeutics is selling its Alzheimer’s disease genetics research program to Eisai after collaborating since 2002. The program is focused on the discovery of Alzheimer’s targets using whole-genome family-based association screening.
The genetics program is one of two TorreyPines discovery programs focused on Alzheimer’s disease, the other being a gamma secretase modulator (GSM) program. TorreyPines is seeking a partner for this program.
“The sale of this asset furthers our transition to a development-only company and enables us to focus our resources on advancing our clinical-stage assets: tezampanel, NGX426, and NGX267,” says Ev Graham, acting CEO of TorreyPines Therapeutics.
NGX267 is in Phase II testing for xerostomia, or dry mouth, secondary to Sjogren’s syndrome. Tezampanel and NGX426 are ionotropic glutamate receptor antagonists that target the AMPA and kainate subtype receptors and have potential in multiple disorders. Tezampanel is in a Phase II program for acute migraine. NGX426 is in Phase I and is the oral version of Tezampanel.